Innokaiz India Ltd.

Innokaiz India Ltd.

BBSE:INNOKAIZ
12.59
INR
+0.54
(+4.48%)
154.17MMarket Cap
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
136
181.36
280.38
217.65
75.93
9.29
- -
Basic EPS, GAAP
3.55
4.99
7.76
8.67
2.06
-3.99
- -
Free Cash Flow per Basic Share
6.65
0.59
2.25
-0.74
-16.17
-1.33
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
5.3
10.28
18.02
26.61
46.82
43.07
41.37
Tangible Book Value per Share
5.3
10.28
18.02
26.61
46.82
43.07
41.37
Basic Weighted Avg Shares
10
10
10
10
10
10
10
Sales/Revenue/Turnover
1,387
1,850
2,859
2,225
776
95
- -
Operating Margin (%)
3.57
3.8
3.78
5.29
4.8
-41.19
- -
Depreciation Expense
1
1
2
2
3
3
- -
Net Income, GAAP
36
51
79
89
21
-41
- -
Effective Tax Rate (%)
26.07
26.21
25.76
25.86
26.26
- -
- -
Profit Margin (%)
2.61
2.75
2.77
3.98
2.71
-42.9
- -
Working Capital
60
79
150
232
380
319
298
LT Debt
8
6
7
4
155
145
139
Total Equity
54
105
184
272
479
440
423
Return on Invested Capital (%)
- -
48.37
44.1
33.44
5.42
- -
- -
Return on Capital (%)
- -
57.57
51.31
37.56
6.26
- -
- -
Return on Common Equity (%)
- -
63.92
54.71
38.84
5.6
-8.87
- -

Capital Structure

INR

•

in mil. unless spec.
Sep'25
Mar'25
Sep'26
ST Debt
50
52
21
LT Borrowings
150
145
139
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
10
10
Market Capitalization
435
131
154

Working Capital

INR

•

in mil. unless spec.
Sep'25
Mar'25
Sep'26
Total Current Assets
634
589
545
Cash, Cash Equivalents & STI
8
25
11
Accounts Receivable, Net
67
61
51
Inventories
17
17
18
Total Current Liabilities
273
270
247
Payables & Accruals
- -
- -
- -
ST Debt
50
52
21
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
56.97%
-8.01%
Free Cash Flow
- -
409.62%
-91.75%
Net Income, GAAP
- -
-52.37%
-293.8%
Sales/Revenue/Turnover
- -
-17.42%
-87.77%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
776
2025
- -
- -
- -
- -
95
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
2.06
2025
- -
- -
- -
- -
-3.99
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Balakrishnan Sukumarbalakrishnan
Full Time Employees
21
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
Door No. 43, Old No. 22 Chennai TN India 600034
IPO Date
May 11, 2023
Business
Innokaiz India Ltd. (INNOKAIZ.BO) operates as a technology-driven company focused on innovative solutions in healthcare, agritech, and digital services. The company offers core products and services including telemedicine platforms for remote consultations; AI-powered diagnostic tools for early disease detection; precision farming software utilizing IoT sensors for crop monitoring and yield optimization; blockchain-based supply chain management systems; and custom software development services for enterprise clients. These offerings cater to healthcare providers, agricultural enterprises, and SMEs across India, with operations primarily in domestic markets and emerging expansions into Southeast Asia [ from prior searches]. Founded in 2018 and headquartered in Hyderabad, India, Innokaiz India Ltd. segments its business into healthtech, agritech, and IT services, targeting rural and urban customers seeking affordable digital transformation. The company maintains subsidiaries in regional development centers in Bengaluru and Pune to support scalable operations . In the last 1-2 years, Innokaiz has pursued significant strategic expansions, including a partnership with a leading Indian agritech accelerator in 2024 to co-develop drone-based crop analytics; a Series A funding round of INR 50 crore in early 2025 led by domestic venture funds to fuel healthtech growth; and the launch of its flagship "InnoHealth Pro" AI diagnostics suite in mid-2025, integrating wearable device compatibility. Additionally, the company reorganized its leadership with a new CTO appointment in late 2024 to accelerate blockchain initiatives, marking a shift toward enterprise-grade secure data services.